BSE Code: | NSE Code: | ISIN: | Sector:
Research Report Detail
|Report Date||Call||Price@Call||Target Price
|Current Status||Time Horizon|
|Target Hit|| Long (1Y)
Edelweiss Maintains ‘Hold’ On Glenmark Pharmaceuticals
Edelweiss says Glenmark Pharmaceuticals20Niche launches have been pushed to FY19 and current cash flows are insufficient to take care of current cost structure. Out-licensing deals over the next 12 months could lend some upside, the brokerage adds.